Effect of Long Term Treatment with Calcitriol on Calcium Absorption and Mineral Metabolism in Postmenopausal Osteoporosis*

1985 ◽  
Vol 61 (3) ◽  
pp. 457-461 ◽  
Author(s):  
B. LAWRENCE RIGGS ◽  
KAREN I. NELSON
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Calcium Absorption ◽  
Mineral Metabolism ◽  
Term Treatment ◽  
Long Term Treatment

Decreased responsiveness to chronic salmon calcitonin treatment in rat kidney and calvaria studied using quantitative enzyme cytochemistry

1985 ◽  
Vol 108 (4) ◽  
pp. 570-576
Author(s):  
D. Michael Salmon ◽  
M. Azria ◽  
Joan M. Zanelli
Keyword(s):  
Alkaline Phosphatase ◽  
Salmon Calcitonin ◽  
Mineral Metabolism ◽  
Bone Alkaline Phosphatase ◽  
Term Treatment ◽  
Target Tissue ◽  
Intracellular Enzyme ◽  
Long Term Treatment ◽  
And Control

Abstract. Growing rats were treated with daily im doses of salmon calcitonin (sCT) (2, 15 and 100 IU/kg) for various times (1, 4 and 24 weeks). The effects on intracellular enzyme activities in bone and kidney were monitored using quantitative cytochemical methods previously developed for the identification of specific target tissue responses to calcitonins. The basal alkaline phosphatase activities in both kidney and bone were decreased by long-term treatment at all time periods and doses tested. No change was noted in basal Ca ATPase activities in kidney after treatment. The capacity of target tissues in chronically treated and control rats to respond to an acute iv dose of sCT was also compared. Acute provocation tests in treated and control rats showed that the renal alkaline phosphatase response was decreased in the rats receiving long-term treatment. Moreover, the direction of response was reversed in chronically treated rats when bone alkaline phosphatase and renal Ca-dependent ATPase activity was measured after acute provocation with sCT, i.e. bone alkaline phosphatase was stimulated instead of being inhibited and renal Ca ATPase was inhibited instead of being stimulated. The application of quantitative cytochemial techiques has demonstrated intracellular changes in enzyme activites in both kidney and bone. The impaired sCT responsiveness can be detected at shorter times of treatment (1 week) and lower doses (2 IU/kg) than has previously been possible by measurement of indices of mineral metabolism in plasma or urine.

Long-term treatment of postmenopausal osteoporosis with sodium etidronate or calcitonin

1996 ◽  
Vol 6 (S1) ◽  
pp. 254-254
Author(s):  
C. Lozano-Tonkin ◽  
M. A. González ◽  
L. García ◽  
J. Jareño
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Predictive Factors for Achievement of Treatment Goals in Patients with Postmenopausal Osteoporosis Treated with Denosumab

2021 ◽  
Author(s):  
Kyosuke Hattori ◽  
Nobunori Takahashi ◽  
Toshihisa Kojima ◽  
Shiro Imagama
Keyword(s):  
Bone Mineral Density ◽  
Multivariate Analysis ◽  
Postmenopausal Osteoporosis ◽  
Predictive Factors ◽  
Term Treatment ◽  
Treatment Goals ◽  
Mineral Density ◽  
T Score ◽  
Long Term Treatment

Abstract Objectives To investigate efficacy of long-term treatment with denosumab and predictive factors for achievement of treatment goals in patients with postmenopausal osteoporosis (PMO). Methods We enrolled 111 PMO patients who had T-scores ≤ -2.5 either at the lumbar spine (L-) or femoral neck (FN-), who had never been treated for osteoporosis, and who could be followed for at least 3 years. We first evaluated changes in bone mineral density (BMD) for up to 7 years. We next defined the treatment goal as the achievement of a T-score > -2.5 at month 36 and performed multivariate analysis to identify predictive factors for achievement of the goal. Results L- and FN-BMD increased yearly for 7 years. Among 87 patients with baseline L-T-scores ≤ -2.5, better baseline L-T-scores predicted achievement of L-T-scores > -2.5 at month 36. The cut-off value for baseline L-T-score was -3.4. Among 76 patients with baseline FN-T-scores ≤ -2.5, better baseline FN-T-scores predicted achievement of FN-T-scores > -2.5 at month 36. The cut-off value for baseline FN-T-scores was -2.8. Conclusions Long-term treatment with denosumab was effective in PMO patients. As better baseline T-score predicted achievement of T-scores > -2.5, early initiation of treatment will contribute to better outcome.

Long-term treatment with calcitriol in postmenopausal osteoporosis

Metabolism ◽  
1990 ◽  
Vol 39 (4) ◽  
pp. 43-49 ◽  
Author(s):  
A. Caniggia ◽  
R. Nuti ◽  
F. Lore ◽  
G. Martini ◽  
V. Turchetti ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Term Treatment ◽  
Long Term Treatment

Long-term treatment of osteoporosis with 24,25 dihydroxycholecalciferol

1982 ◽  
Vol 101 (4) ◽  
pp. 636-640 ◽  
Author(s):  
J. Reeve ◽  
M. Tellez ◽  
J. R. Green ◽  
R. Hesp ◽  
U. Elsasser ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Calcium Absorption ◽  
Statistical Significance ◽  
Term Treatment ◽  
Bone Blood Flow ◽  
Treatment Of Osteoporosis ◽  
Dihydroxyvitamin D ◽  
Long Term Treatment ◽  
Term Benefit

Abstract. Five patients with involutional osteoporosis were treated with 24,25 dihydroxycholecalciferol (24,25-(OH)2D3) for 6 months, in doses sufficient to double plasma levels at that time. Dietary calcium absorption transiently improved by nearly 2 mmol Ca per day at 2 weeks, but this effect was lost by 6 months. The calcium and phosphate balances followed the trends in calcium absorption. Only twenty-five dihydroxyvitamin D levels changed little. Histomorphometric and kinetic indices of new bone formation and bone blood flow remained stable but there was an increase in urine hydroxyproline at 6 months, which was of borderline statistical significance. Treatment at this dosage of 24,25(OH)2D3, which increased plasma levels within the physiological range, conferred no measurable long-term benefit on our patients. Larger doses, or combination therapy, may warrant further clinical evaluation in osteoporosis.

Effect of Long-term Treatment with 1^|^alpha; (OH)D3-hydroxyvitamin D3 on Postmenopausal Osteoporosis

1997 ◽  
Vol 73 (6) ◽  
pp. 651-658
Author(s):  
Masanori KANATANI ◽  
Toshitsugu SUGIMOTO ◽  
Yasuhide TOKKODA ◽  
Kazuo CHIHARA
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Term Treatment ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document